[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-neoplasm":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":40,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100610425","phase-1-symbiotic-gu-08-a-study-to-learn-about-the-medicine-called-pf-08634404-dosed-alone-and-in-combination-with-other-anticancer-therapies-in-adults-with-locally-advanced-or-metastatic-renal-cell-cancer-100610425",false,"NCT07227415","Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","AN INTERVENTIONAL PHASE 1B\u002F2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA","Inclusion Criteria:\n\n* 18 years of age or older at screening\n* Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology\u002Fcytology\n* At least one measurable (as defined by the investigator) and untreated lesion\n* Adequate hematologic, hepatic, cardiac and renal function\n* No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \\>12 months prior)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories\n\nExclusion Criteria:\n\nParticipants may be excluded if they meet any of the following:\n\n* Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.\n* Clinically significant risk of haemorrhage or fistula\n* History of another malignancy within 3 years\n* History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n* active autoimmune diseases requiring systemic treatment within the past 2 years\n* uncontrolled cardiac and other comorbidities within 6 months prior to the first dose\n* Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study\n* History of severe bleeding tendency or coagulation dysfunction\n* History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose\n* Acute, chronic or symptomatic infections\n* Participants with history of immunodeficiency","ALL","18 Years",{"count":19,"type":20},224,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.\n\nTo join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.\n\nParticipants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Carcinoma, Renal Cell","Advanced Renal Cell Carcinoma","Renal Cancer","Renal Neoplasm","Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell Metastasis","Advanced or Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell, Advanced","Metastatic Renal Cell Cancer","Metastatic Renal Cell Carcinoma ( mRCC)","Metastatic\u002FAdvanced Renal Cell Carcinoma",[41,42,43],"Renal cell carcinoma","renal cancer","renal neoplasm","RECRUITING","2026-06-03",{"date":47,"type":48},"2026-06-04","ACTUAL",{"date":50,"type":48},"2026-02-10",{"date":52,"type":20},"2028-11-01",{"name":54,"class":55},"Pfizer","INDUSTRY",109,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100503959","phase-2-nsaid-use-after-robotic-partial-nephrectomy-100503959","NCT05842044","NSAID Use After Robotic Partial Nephrectomy","NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial","No-PAIN","Inclusion Criteria:\n\n* Patients undergoing uncomplicated robotic assisted laparoscopic partial nephrectomy for renal mass at the University of Miami Hospital and Network Sites (Deerfield Beach, Plantation, Lennar (Coral Gables), and Kendal).\n* Age 18-99.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Allergy to NSAIDs\n* Myocardial infarction or unstable angina within 12 months.\n* Any history of coronary artery bypass graft surgery.\n* History or active peptic ulcer disease, gastrointestinal (GI) bleeding, GI perforation. History of bleeding disorder. Glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1.73m2 (Modification of Diet in Renal Disease (MDRD) equation).\n* Taking any anti-platelet or anti-coagulation medications concurrently (e.g. warfarin, aspirin, clopidogrel, rivaroxaban etc.)\n* Chronic opioid use (use within 12 weeks) or history of opioid use disorder.\n* Solitary kidney.\n* Pregnancy.\n* Inability to give informed consent or unable to meet requirement of the study for any reason.","99 Years",{"count":67,"type":20},110,[24],"The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.",[71,29,30],"Kidney Cancer",[73],"Non-steroidal anti-inflammatory drugs (NSAIDs)","2025-09-03",{"date":76,"type":48},"2025-09-05",{"date":78,"type":48},"2023-09-15",{"date":80,"type":20},"2026-09-30",{"name":82,"class":83},"University of Miami","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":84},"100554591","dexamethasone-versus-mg-added-to-bupivacaine-used-in-espb-for-perioperative-pain-control-in-patients-undergoing-unilateral-nephrectomy-100554591","NCT06501079","Dexamethasone Versus Mg Added to Bupivacaine Used in ESPB for Perioperative Pain Control in Patients Undergoing Unilateral Nephrectomy","The Efficacy of Dexamethasone Versus Magnesium Sulphate Added to Bupivacaine Used in Erector Spinae Plane Block for Perioperative Pain Control in Patients Undergoing Unilateral Nephrectomy","Inclusion Criteria:\n\n* Adult (18 - 65)\n* Patients undergoing unilateral nephrectomy\n* ASA II \u002F III\n\nExclusion Criteria:\n\n* Patient refusal\n* Age less than 18 years\n* Allergy to any of the studied medications\n* Mid line incision\n* Bilateral nephrectomy\n* Distorted anatomy of the back (e.g. kyphoscoliosis)\n* Known neurologic disorders, psychiatric disorder or chronic pain\n* Local infection\n* Hemodynamic instability","65 Years",{"count":94,"type":20},78,[96],"NA","Aim of the study:\n\nThe current study aims to compare the effect of adding dexamethasone versus magnesium sulfate to bupivacaine in ultrasound-guided erector spinae plane block on the severity of postoperative pain.\n\nPrimary Objectives:\n\n\\- To compare the effect of ESPB without additives to the effect of adding dexamethasone and to the impact of adding magnesium sulfate in the form of post-operative morphine consumption",[30],[100,101,102,103,104,105,106],"Dexamethasone","Magnesium Sulphate","Bupivacaine","Erector Spinae Plane Block","perioperative","pain control","unilateral nephrectomy","2024-07-11",{"date":109,"type":48},"2024-07-15",{"date":111,"type":48},"2024-05-01",{"date":113,"type":20},"2024-12-01",{"name":115,"class":83},"National Cancer Institute, Egypt"]